Impact of dose intensity of ponatinib on selected adverse events: Multivariate analyses from a pooled population of clinical trial patients
详细信息 查看全文
- 作者：David J. Dorera ; david.dorer@ariad.com" class="auth_mail" title="E-mail the corresponding author ; Ronald K. Knickerbockera ; ronald.knickerbocker@ariad.com" class="auth_mail" title="E-mail the corresponding author ; Michele Baccaranib ; michele.baccarani@unibo.it" class="auth_mail" title="E-mail the corresponding author ; Jorge E. Cortesc ; jcortes@mdanderson.org" class="auth_mail" title="E-mail the corresponding author ; Andreas Hochhausd ; andreas.hochhaus@med.uni-jena.de" class="auth_mail" title="E-mail the corresponding author ; Moshe Talpaze ; mtalpaz@med.umich.edu" class="auth_mail" title="E-mail the corresponding author ; Frank G. Haluskaa ; frank.haluska@ariad.com" class="auth_mail" title="E-mail the corresponding author
- 关键词：BCR-ABL1 ; Chronic myeloid leukemia ; Dose intensity ; Philadelphia chromosome ; Ponatinib ; Tyrosine kinase inhibitor
- 刊名：Leukemia Research
- 出版年：2016
- 出版时间：September 2016
- 年：2016
- 卷：48
- 期：Complete
- 页码：84-91
- 全文大小：1556 K
文摘
- class="listitem" id="list_lis0005">
- class="label">•
Ponatinib dose intensity was shown to be associated with rates of adverse events.
- class="label">•
Pancreatitis, rash, and cardiac failure were most strongly associated with dose.
- class="label">•
Time-to-event analyses suggest a lag between changes in dose and event risk.
- class="label">•
No association between dose intensity and venous thromboembolic events was evident.
- class="label">•
Results support investigating approaches to lower average ponatinib dose intensity.